A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 49
- Registration Number
- NCT01290731
A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 106
- Registration Number
- NCT01288209
A Study of Paliperidone Palmitate in Japanese Patients With Schizophrenia
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 201
- Registration Number
- NCT01258920
Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer
- First Posted Date
- 2010-08-23
- Last Posted Date
- 2017-10-23
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 27
- Registration Number
- NCT01186484
An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 91
- Registration Number
- NCT01124604
A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2014-01-13
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 91
- Registration Number
- NCT01124617
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 387
- Registration Number
- NCT01081795
A Confirmatory Study of Fentanyl in Participants With Post-herpetic Neuralgia, Complex Regional Pain Syndrome or Postoperative Pain Syndrome
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 258
- Registration Number
- NCT01008553
A Confirmatory Study of Fentanyl in Participants With Osteoarthritis or Low Back Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 218
- Registration Number
- NCT01008618
A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 92
- Registration Number
- NCT00996476
© Copyright 2024. All Rights Reserved by MedPath